Results 51 to 60 of about 8,835 (210)

The thyroid, the eyes and the gut: a possible connection [PDF]

, 2017
Graves’ disease (GD) is an autoimmune disorder responsible for 60–90% of thyrotoxicosis, with an incidence of 1 to 2 cases per 1000 population per year in England.
Covelli, D., Ludgate, Marian Elizabeth
core   +2 more sources

Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease

Acta Ophthalmologica, Volume 104, Issue 1, Page e28-e38, February 2026.
Abstract Purpose To examine ocular surface changes and inflammatory tear fluid biomarkers in patients with thyroid eye disease (TED). Methods We included 106 Graves' disease (GD) patients (36 without TED, 32 with active and 38 with inactive TED) and 106 age‐ and sex‐matched healthy subjects for ophthalmological evaluation, including ocular surface ...
Mikael Thomassen Neset, Roy Miodini Nilsen, Kristian Løvås, Kathrine Halsøy, Håkon Reikvam, Ann‐Elin Meling Stokland, Grethe Åstrøm Ueland, Anette S. B. Wolff, Hans Christian D. Aass, Sjur Reppe, Eystein Sverre Husebye, Eyvind Rødahl, Tor Paaske Utheim, Hans Olav Ueland   +13 more
wiley   +1 more source

Practical Guidelines Management of Graves Ophthalmopathy

Acta Medica Indonesiana, 2020
Graves’ ophthalmopathy is the most common extra-thyroid manifestation in patients with Graves’ disease, based on inflammatory and autoimmune conditions in orbital tissue.
Imam Subekti, Pradana Soewondo, Suharko Soebardi, Budiman Darmowidjojo, Dante Saksono Harbuwono, Dyah Purnamasari, Tri Juli Edi Tarigan, Wismandari Wisnu, Dicky Levenus Tahapary, Farid Kurniawan, M Sidik, Syntia Nusanti, Salmarezka Dewiputri, Hernawita Suharko, Gusti G Suardana, Indrati Suroyo, Vally Wulani, Alvita Dewi Siswoyo, Soehartati Gondhowiardjo, Henry Kodrat   +19 more
doaj   +2 more sources

Thyroid Associated Ophthalmopathy

, 2004
Thyroid-related immune orbitopathy (TRIO) has a variety of names previously, such as Graves’ ophthalmopathy, ophthalmic Graves’ disease, and thyroid-associated ocular disease. Although their names are different, their clinical characteristics are the same, that is, abnormal thyroid endocrine axis (endocrine hormones secreted by the thyroid, pituitary ...
Jianmin Ma, Yun Feng
  +6 more sources

Inactive Graves' ophthalmopathy and self-esteem [PDF]

, 2008
PURPOSE: To assess the self-esteem of Graves' ophthalmopathy patients in the inactive phase. METHODS: Thirty euthyroid patients were evaluated in the inactive phase of disease with age ranging from 26 to 65 years, average of 43 ± 11,0 years, called study
Ferreira, Lydia Masako, Magalhães, Carlos Henrique de Toledo, Manso, Paulo Góis, Novo, Neil Ferreira, Pereira, Max Domingues, Veiga, Daniela Francescato   +5 more
core   +2 more sources

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition

Advanced Science, Volume 13, Issue 4, 19 January 2026.
This study presents YC3, a novel inhibitory TSHR‐targeting aptamer, as a promising therapeutic for Graves' ophthalmopathy (GO). YC3 suppresses pathological phenotypes in human orbital fibroblasts and improves outcomes in GO mice by binding to a previously unidentified allosteric site on TSHR, demonstrating the potential of aptamers in advancing ...
Yanchen Zhang, Ende Wu, Weibin Liu, Ling Zeng, Neng Ling, Hongmei Wang, Zhixing Li, Shuang Yao, Tonghe Pan, Xuanwen Li, Yate Huang, Xiaojing Li, Yunhai Tu, Wentao Yan, Jianzhang Wu, Mao Ye, Wencan Wu   +16 more
wiley   +1 more source

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition (Adv. Sci. 4/2026)

Advanced Science, Volume 13, Issue 4, 19 January 2026.
An Allosteric Strategy for Thyroid Eye Disease This illustration depicts an aptamer (purple) binding to the target protein (white) at an allosteric site. This strategic binding induces a conformational change that acts as a shield, preventing pathogenic autoantibodies (red) from initiating the disease cascade, while leaving the protein's normal ...
Yanchen Zhang, Ende Wu, Weibin Liu, Ling Zeng, Neng Ling, Hongmei Wang, Zhixing Li, Shuang Yao, Tonghe Pan, Xuanwen Li, Yate Huang, Xiaojing Li, Yunhai Tu, Wentao Yan, Jianzhang Wu, Mao Ye, Wencan Wu   +16 more
wiley   +1 more source

Orbital lymphoma associated with Graves’ disease: A case report [PDF]

Vojnosanitetski Pregled, 2014
Introduction. The presence of bilateral exophthalmos and palpebral, periorbital edema associated with hyperthyroidism is most often considered as an initial sign of Graves’ ophthalmopathy.
Hajduković Zoran, Kuzmić-Janković Snežana, Kljaković-Avramović Tamara, Sekulović Leposava, Tukić Ljiljana   +4 more
doaj   +1 more source

Building the case for insulin-like growth factor receptor-I involvement in thyroid-associated ophthalmopathy [PDF]

, 2017
The pathogenesis of orbital Graves' disease (GD), a process known as thyroid-associated ophthalmopathy (TAO), remains incompletely understood. The thyrotropin receptor (TSHR) represents the central autoantigen involved in GD and has been proposed as the ...
Janssen, J.A.M.J.L. (Joop), Smith, T.J. (Terry)   +1 more
core   +4 more sources

Exploring the Therapeutic Mechanism of Xiehuo Pingtu San in Treating Thyroid Eye Disease Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation

International Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Background Xiehuo Pingtu San (XHPTS) has been shown to be safe and effective in treating thyroid eye disease (TED), yet its underlying mechanisms remain unclear. This study aimed to elucidate the active ingredients of XHPTS and their therapeutic mechanisms in TED through network pharmacology, molecular docking, and molecular dynamics simulations ...
Ping Wang, Ruiyan Liu, Xin Shang, Yu Fu, Ying Wang, Shuxun Yan, Suraiya Saleem   +6 more
wiley   +1 more source